Abstract: Embodiments of the present disclosure generally relate to methods and apparatus for measuring and controlling local impedances at a substrate support in a plasma processing chamber during processing of a substrate. A substrate support includes a plurality of substrate support pins wherein the radio frequency voltage, current and phase of each of the plurality of substrate support pins are measured and impedances of the support pins are adjusted in real time. Each of the substrate support pins is coupled to an associated adjustable impedance circuit that may be remotely controlled. In one embodiment a variable capacitor is used to adjust the impedance of the impedance circuit coupled to the associated substrate support pin and may be remotely adjusted with a stepper motor.

Abstract: In some implementations, a network daemon can manage access to a mobile device's network interface. The network daemon (e.g., network connection managing process) can monitor the condition of the mobile device's network connection on one or more interfaces. The network daemon can monitor many conditions on the mobile device. The network daemon can receive background networking requests from network clients (e.g., processes, applications) that specify criteria for initiating a network connection. The network daemon can then smartly manage network connections taking into account network conditions, mobile device conditions and/or client criteria received in the client request. This can help reduce battery life impact, memory usage, likelihood of call drops, data usage cost, and load on network operators.

Abstract: In some implementations, a network daemon can manage access to a mobile device's network interface. The network daemon (e.g., network connection managing process) can monitor the condition of the mobile device's network connection on one or more interfaces. The network daemon can monitor many conditions on the mobile device. The network daemon can receive background networking requests from network clients (e.g., processes, applications) that specify criteria for initiating a network connection. The network daemon can then smartly manage network connections taking into account network conditions, mobile device conditions and/or client criteria received in the client request. This can help reduce battery life impact, memory usage, likelihood of call drops, data usage cost, and load on network operators.

Abstract: Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.

Abstract: Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.

Abstract: In some implementations, a network daemon can manage access to a mobile device's network interface. The network daemon (e.g., network connection managing process) can monitor the condition of the mobile device's network connection on one or more interfaces. The network daemon can monitor many conditions on the mobile device. The network daemon can receive background networking requests from network clients (e.g., processes, applications) that specify criteria for initiating a network connection. The network daemon can then smartly manage network connections taking into account network conditions, mobile device conditions and/or client criteria received in the client request. This can help reduce battery life impact, memory usage, likelihood of call drops, data usage cost, and load on network operators.

Abstract: In some implementations, a network daemon can manage access to a mobile device's network interface. The network daemon (e.g., network connection managing process) can monitor the condition of the mobile device's network connection on one or more interfaces. The network daemon can monitor many conditions on the mobile device. The network daemon can receive background networking requests from network clients (e.g., processes, applications) that specify criteria for initiating a network connection. The network daemon can then smartly manage network connections taking into account network conditions, mobile device conditions and/or client criteria received in the client request. This can help reduce battery life impact, memory usage, likelihood of call drops, data usage cost, and load on network operators.

Abstract: Disclosed is a population of nanoparticles, together with methods of making a population of nanoparticles, wherein one or more of the nanoparticles includes: an amorphous drug core having an effective diameter less than or equal to about 2.0 microns, wherein the amorphous drug core is substantially free of dopant, and wherein the amorphous drug core includes a drug with properties that satisfy the following relationships: a glass transition temperature greater than or equal to about 50 Deg. C., a glass forming ability less than or equal to about 0.85; and water solubility at 25 Deg. C. less than or equal to about 1 mg/ml; and at least one stabilizer adsorbed on a surface of the amorphous drug core; and wherein the population of nanoparticles exhibits greater than about six months amorphous stability.

Abstract: Disclosed is a population of nanoparticles, together with methods of making a population of nanoparticles, wherein one or more of the nanoparticles includes: an amorphous drug core having an effective diameter less than or equal to about 2.0 microns, wherein the amorphous drug core is substantially free of dopant, and wherein the amorphous drug core comprises a drug with properties that satisfy the following relationships: a glass transition temperature greater than or equal to about 30 Deg. C.; and water solubility at 25 Deg. C. less than or equal to about 1 mg/ml; and at least one stabilizer adsorbed on a surface of the amorphous drug core; and wherein the at least one stabilizer is present in an amount effective to provide an amorphous stability of the population of nanoparticles that is approximately equal to or greater than an amorphous stability of an amorphous bulk drug substance comprising the drug, as measured over a period of at least four months.

Abstract: Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.

Abstract: Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.

Abstract: Oral delivery vehicles and compositions for providing sustained release of secondary amines including reboxetine with reduced formate poly(alkylene oxide) polymers are provided. Processes for reducing the amount of the formic compounds from the polymers comprising contacting the polymers with an acid having a Pka lower than that of formic acid are also disclosed.

Abstract: Dosage forms and methods for providing sustained release of reboxetine are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma reboxetine concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma reboxetine concentration occurrence in each 24 hour period. In addition, the peak plasma reboxetine concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma reboxetine concentration that occurs following administration of reboxetine in an immediate-release dosage form.

Abstract: Dosage forms and methods for providing sustained release of reboxetine are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma reboxetine concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma reboxetine concentration occurrence in each 24 hour period. In addition, the peak plasma reboxetine concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma reboxetine concentration that occurs following administration of reboxetine in an immediate-release dosage form.

Abstract: Dosage forms and methods for providing sustained release of reboxetine are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma reboxetine concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma reboxetine concentration occurrence in each 24 hour period. In addition, the peak plasma reboxetine concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma reboxetine concentration that occurs following administration of reboxetine in an immediate-release dosage form.

Abstract: Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.

Abstract: A tumble dryer article comprising: a mixture of at least two surfactants, (i) a first surfactant present in an amount of about 5 wt. % to about 70 wt. % and having an endotherm peak temperature of from about 75.degree. C. to about 155.degree. C., (ii) a second surfactant present in an amount of about 30 wt. % to about 95 wt. % and having an endotherm peak temperature of from about 35.degree. C. to about 70.degree. C., wherein the peak temperatures of the first and second surfactant of the mixture are different from each other by at least about 1.degree. C. as measured in a differential scanning calorimeter device and a melting transition temperature of the mixture being from about 50.degree. C. to about 120.degree. C.; and dispenser means for dispensing the mixture onto fabrics in a tumble dryer.

Abstract: A tumble dryer article comprising an effective amount of a fabric conditioning composition containing from about 60 to about 99 wt. % of a hydrocarbon based fabric conditioning componenta) an effective amount of a fabric conditioning composition having(i) from about 60 to about 99 wt. % of a hydrocarbon based fabric conditioning component; and(ii) 0.5 wt. % to 30 wt. % perfume capsules consisting essentially of a water soluble natural or modified natural or synthetic polymer and 1% to 70% perfume, the fabric conditioning composition having 10 wt. % or less free water when 0.5 wt. % to 10 wt. % perfume capsules are present and a free water to perfume capsules ratio of less than about 1 when more than 10 wt. % perfume particles are present; andb) dispensing means for dispensing the fabric conditioning composition onto fabrics in a tumble dryer.